NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC decreased its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 4.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 837,368 shares of the company’s stock after selling 35,169 shares during the quarter. TimesSquare Capital Management LLC owned approximately 0.74% of NewAmsterdam Pharma worth $23,815,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in NewAmsterdam Pharma in the first quarter valued at $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of NewAmsterdam Pharma by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock valued at $5,898,000 after buying an additional 34,563 shares in the last quarter. KLP Kapitalforvaltning AS raised its position in NewAmsterdam Pharma by 51.7% during the second quarter. KLP Kapitalforvaltning AS now owns 9,100 shares of the company’s stock worth $165,000 after acquiring an additional 3,100 shares during the period. Teacher Retirement System of Texas purchased a new position in NewAmsterdam Pharma during the second quarter valued at $212,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of NewAmsterdam Pharma in the second quarter valued at about $6,392,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $33.25, for a total value of $199,500.00. Following the sale, the insider directly owned 73,481 shares of the company’s stock, valued at approximately $2,443,243.25. This represents a 7.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Louise Frederika Kooij sold 75,117 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $36.21, for a total transaction of $2,719,986.57. Following the completion of the transaction, the chief accounting officer owned 15,000 shares in the company, valued at $543,150. This represents a 83.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 298,647 shares of company stock valued at $10,236,050 in the last quarter. Company insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Stock Down 0.7%

NASDAQ:NAMS opened at $34.63 on Monday. The stock has a market capitalization of $3.93 billion, a price-to-earnings ratio of -16.89 and a beta of 0.06. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $42.00. The stock’s fifty day moving average is $34.04 and its two-hundred day moving average is $32.22.

Analysts Set New Price Targets

A number of brokerages have commented on NAMS. The Goldman Sachs Group increased their target price on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a report on Tuesday, December 2nd. Leerink Partners reiterated an “outperform” rating and set a $55.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. HC Wainwright started coverage on NewAmsterdam Pharma in a report on Monday, October 20th. They issued a “buy” rating and a $52.00 target price for the company. Needham & Company LLC boosted their price target on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, Royal Bank Of Canada lifted their target price on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.